8 results about "Genus Shigella" patented technology

Provided herein are vaccine compositions for preventing and combating infection by Shigella. In particular, the present disclosure provides a composition comprising a Shigella virulence factor VirG (or IcsA) protein or a fragment thereof comprising about 100-400 amino acids of the VirG protein having an amino acid sequence that is at least 90% identical to the sequence set forth in SEQ ID NO: 2.

The invention relates to shigella flexneri as well as related serotype and application of a preparation of the shigella flexneri in preparation of anti-tumor immune activation and treatment medicines. The shigella flexneri and the preparation thereof disclosed by the invention can improve a tumor immune microenvironment by activating anti-tumor immune response of an organism so as to inhibit tumor growth, and are suitable for prevention and / or treatment of various tumors; the strain and the preparation thereof can be independently used and can also be combined with existing tumor therapies such as chemotherapy, radiotherapy and immunotherapy to synergistically enhance the anti-tumor curative effect; the invention provides a new microbial resource and strategy for tumor immunotherapy, and has an important clinical application prospect.

The invention relates to application of a scavenger receptor A antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention and treatment. Aiming at the technical problem that in the prior art, the drug resistance of plasmodium to drugs and the resistance of mosquito vector to insecticides are increasingly serious, so that the malaria propagation control effect is reduced, the invention provides a scavenger receptor A antibody which is specifically combined with a scavenger receptor A on the surface of macrophage to inhibit the phagocytic function of the scavenger receptor A, so that the control effect of malaria propagation is improved. Therefore, the proliferation of antimalarial active bacteria (such as Elizabeth, shigella sonnei or klebsiella oxytoca) in the stomach of the anopheles is promoted, and the development of plasmodium in the midgut of the anopheles is indirectly blocked. The antibody can be used alone or in combination with a Pfs25 antibody. The anopheles infection rate and the number of oocysts are remarkably reduced (for example, the infection rate is reduced from 81.7% to 6%), an eco-friendly biological control mode which is not prone to drug resistance is provided, and a new strategy is provided for malaria transmission blocking.

The invention discloses a group of antibacterial polypeptides aiming at gram-negative bacteria, and belongs to the technical field of biological medicines. According to the invention, a group of antibacterial peptides is obtained through screening, and the antibacterial peptides have good broad-spectrum antibacterial performance on escherichia coli, salmonella typhimurium, pseudomonas aeruginosa, klebsiella pneumoniae, shigella sonnei and stenotrophomonas maltophilia. Wherein the hemolytic activity and toxicity of the antibacterial peptides 11A-1, 11A-4 and 11A-5 are lower than therapeutic concentration threshold values, and the antibacterial peptides 11A-1, 11A-4 and 11A-5 can be used for preparing drugs or medical products for treating multi-drug-resistant bacterial infection.

The invention discloses application of pH-ROS dual-response fullerol gel in improvement of intestinal microbiota and colitis, and belongs to the technical field of biological pharmacy. The invention provides an application of pH-ROS dual-response fullerol gel SA-DA / CMCS-FPBA-coated C60 (OH) 12 in treatment of ulcerative colitis by regulating intestinal microbiota. The fullerol gels can treat colitis by promoting a substantial increase in beneficial bacteria of the genus Bifidobacterium, thereby reducing other harmful bacteria and maintaining the levels of probiotics of the genus Shigella, Enterococcus and Fecalis. After being applied, the compound has a potential effect of maintaining the steady state of microorganisms for patients suffering from ulcerative colitis, has the characteristics of low toxicity, high efficiency and the like, and has a good drug development prospect.

The invention belongs to the field of gene detection, and particularly relates to a characteristic gene combination for predicting antibiotic susceptibility phenotype of shigella sonnei, a kit and application of the characteristic gene combination. The drug sensitive phenotype of shigella sonnei to antibiotics is judged by detecting specific genes or mutation, the method has the advantages of high accuracy, high sensitivity and high specificity, and accurate diagnosis and treatment of infection are facilitated.

The invention provides a berberine derivative as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the derivative, an acyl acetophenone substituent group is introduced to the 9 site of berberine, and a series of 9-site substituted berberine compounds are specifically designed and synthesized. In-vitro antimicrobial activity detection shows that the compounds have excellent inhibitory activity on gram-positive bacteria (staphylococcus aureus and methicillin-resistant staphylococcus aureus) and gram-negative bacteria (escherichia coli, shigella flexneri, shigella dysenteriae and vibrio parahaemolyticus), can be used for preparing antibacterial drugs, do not have obvious drug resistance, and can be used for preparing antibacterial drugs. And a more efficient and safer candidate drug can be provided for the treatment of clinical diarrhea related diseases.

The present invention provides protected tetrasaccharides, their process of preparation and their use as common scaffold precursors in the synthesis of oligosaccharides representing segments of the O-antigens from diverse S. flexneri serotypes, comprising for example SF2a, SF3a, SF2b, SF1b, SFX and / or SFY.